NCT00799448View on ClinicalTrials.gov

Comparison of Efficacy and Safety of Repaglinide Combined With Insulin NPH Versus Biphasic Human Insulin 30 Alone in Inadequately Controlled Subjects With Type 2 Diabetes

PHASE4TerminatedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 16, 2003

Primary Completion Date

September 20, 2004

Study Completion Date

September 20, 2004

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

repaglinide

DRUG

biphasic human insulin 30

DRUG

insulin NPH

Trial Locations (1)

15127

Novo Nordisk Investigational Site, Athens

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY